Belumosudil Mesylate Patent Expiration
Belumosudil Mesylate is Used for treating chronic graft-versus-host disease in adults and pediatric patients. It was first introduced by Kadmon Pharmaceuticals Llc
Belumosudil Mesylate Patents
Given below is the list of patents protecting Belumosudil Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rezurock | US12097202 | Methods of administering Belumosudil for treatment of chronic graft versus host disease | Jul 14, 2042 | Kadmon Pharms Llc |
| Rezurock | US11311541 | Treatment of GVHD | Apr 09, 2035 | Kadmon Pharms Llc |
| Rezurock | US10183931 | Rho kinase inhibitors | Oct 07, 2033 | Kadmon Pharms Llc |
| Rezurock | US10696660 | Rho kinase inhibitors | Oct 07, 2033 | Kadmon Pharms Llc |
| Rezurock | US9815820 | Rho kinase inhibitors | Oct 07, 2033 | Kadmon Pharms Llc |
| Rezurock | US8357693 | Pharmacokinetically improved compounds | Oct 30, 2029 | Kadmon Pharms Llc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Belumosudil Mesylate's patents.
Latest Legal Activities on Belumosudil Mesylate's Patents
Given below is the list recent legal activities going on the following patents of Belumosudil Mesylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Jul, 2024 | US8357693 |
| transaction for FDA Determination of Regulatory Review Period | 18 Jan, 2024 | US8357693 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Dec, 2023 | US10696660 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US8357693 |
| Electronic Review Critical | 01 Jun, 2023 | US10696660 |
| Mail Certificate of Correction Memo | 31 May, 2023 | US10696660 |
| Post Issue Communication - Certificate of Correction | 30 May, 2023 | US10696660 |
| Certificate of Correction Memo | 26 May, 2023 | US10696660 |
| Electronic Review Critical | 25 May, 2023 | US10183931 |
| Electronic Review Critical | 25 May, 2023 | US9815820 |
Belumosudil Mesylate's Family Patents
